SEGMENTS (Details)	3 Months Ended
	Mar. 31, 2022 USD ($) Facility	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)
Segment Reporting Information [Abstract]
Number of plasma collection facilities under development | Facility	10
Number of FDA-licensed plasma collection facilities | Facility	5
Revenues	$ 29,103,093	$ 16,048,618
Cost of product revenue	25,441,046	17,770,122
Loss from operations	(14,815,066)	(15,164,249)
Interest and other expense, net	(3,522,850)	(3,215,692)
Loss on extinguishment of debt	(6,669,941)	0
Net loss	(25,007,857)	(18,379,941)
Capital expenditures	2,842,085	2,571,161
Depreciation and amortization expense	1,590,217	1,229,628
Total assets	308,032,492	235,667,028	$ 276,252,724
United States [Member]
Segment Reporting Information [Abstract]
Revenues	27,316,151	13,678,008
International [Member]
Segment Reporting Information [Abstract]
Revenues	1,786,942	2,370,610
Corporate [Member]
Segment Reporting Information [Abstract]
Revenues	35,708	35,708
Cost of product revenue	0	0
Loss from operations	(6,509,288)	(3,687,719)
Interest and other expense, net	(3,472,854)	(3,193,795)
Loss on extinguishment of debt	(6,669,941)
Net loss	(16,652,083)	(6,881,514)
Capital expenditures	0	0
Depreciation and amortization expense	763	1,867
Total assets	61,313,259	61,734,239
Operating Segments [Member] | ADMA BioManufacturing [Member]
Segment Reporting Information [Abstract]
Revenues	25,728,625	13,421,043
Cost of product revenue	22,213,781	15,449,757
Loss from operations	(4,442,684)	(9,505,689)
Interest and other expense, net	(49,267)	(21,513)
Loss on extinguishment of debt	0
Net loss	(4,491,951)	(9,527,202)
Capital expenditures	1,310,379	1,012,980
Depreciation and amortization expense	1,111,951	1,009,770
Total assets	214,150,322	156,535,177
Operating Segments [Member] | Plasma Collection Centers [Member]
Segment Reporting Information [Abstract]
Revenues	3,338,760	2,591,867
Cost of product revenue	3,227,265	2,320,365
Loss from operations	(3,863,094)	(1,970,841)
Interest and other expense, net	(729)	(384)
Loss on extinguishment of debt	0
Net loss	(3,863,823)	(1,971,225)
Capital expenditures	1,531,706	1,558,181
Depreciation and amortization expense	477,503	217,991
Total assets	$ 32,568,911	$ 17,397,612